The therapeutic effect of highly malignant triple negative breast cancer (TNBC) is negatively
affected by the formation of tumor cell resistant clone and the severe toxicity of …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Objective Use of the frailty index to measure an accumulation of deficits has been proven a
valuable method for identifying elderly people at risk for increased vulnerability, disease …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Inflammation is a response to a lesion in the tissue or infection. This process occurs in a
specific manner in the central nervous system and is called neuroinflammation, which is …

Abstract The design of Antibody Drug Conjugates (ADCs) as efficient targeting agents for
tumor cell is still in its infancy for clinical applications. This approach incorporates the …

Highlights•Albeit their clinical success, ADCs have a relatively narrow therapeutic
index.•Dose-limiting toxicities of ADCs are frequently unrelated to the targeted …

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by
aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still …

Antibody-drug conjugates (ADCs) are a promising therapeutic modality for oncology
indications. The concept of an ADC platform is to increase the therapeutic index (TI) of …

The therapeutic utility of antibodies and their derivatives is achieved by various means. The
FDA has approved several targeted antibodies that disrupt signaling of various growth factor …